C R Bard Inc (NYSE:BCR) was the recipient of a large decrease in short interest in April. As of April 28th, there was short interest totalling 579,444 shares, a decrease of 50.2% from the April 13th total of 1,163,215 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average trading volume of 2,488,702 shares, the short-interest ratio is currently 0.2 days.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded C R Bard from a “buy” rating to a “hold” rating in a research note on Friday. Raymond James Financial, Inc. reaffirmed a “market perform” rating and set a $265.00 price target on shares of C R Bard in a research note on Tuesday, April 25th. Cowen and Company raised their price target on C R Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a research note on Monday, April 24th. Wells Fargo & Co downgraded C R Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. Finally, JMP Securities raised their price target on C R Bard from $240.00 to $255.00 in a research note on Friday, January 27th. Twelve investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $263.21.

Shares of C R Bard (NYSE:BCR) opened at 308.02 on Tuesday. The firm has a market cap of $22.31 billion, a price-to-earnings ratio of 39.20 and a beta of 0.63. The firm has a 50-day moving average price of $274.14 and a 200-day moving average price of $240.57. C R Bard has a 12-month low of $203.63 and a 12-month high of $309.16.

C R Bard (NYSE:BCR) last posted its earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, beating the consensus estimate of $2.65 by $0.22. C R Bard had a return on equity of 48.48% and a net margin of 14.31%. The company had revenue of $938.80 million for the quarter, compared to the consensus estimate of $916.15 million. During the same quarter in the prior year, the business earned $2.34 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Equities research analysts anticipate that C R Bard will post $11.78 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, May 12th. Stockholders of record on Monday, May 1st were given a $0.26 dividend. This represents a $1.04 annualized dividend and a dividend yield of 0.34%. The ex-dividend date of this dividend was Thursday, April 27th. C R Bard’s payout ratio is 14.77%.

In related news, VP Frank Lupisella, Jr. sold 3,622 shares of the stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $304.00, for a total value of $1,101,088.00. Following the completion of the sale, the vice president now directly owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jim C. Beasley sold 4,390 shares of the stock in a transaction dated Tuesday, February 21st. The stock was sold at an average price of $245.00, for a total value of $1,075,550.00. Following the completion of the sale, the insider now directly owns 26,625 shares of the company’s stock, valued at $6,523,125. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the stock. Carderock Capital Management Inc. increased its position in C R Bard by 48.9% in the third quarter. Carderock Capital Management Inc. now owns 18,175 shares of the medical instruments supplier’s stock valued at $4,076,000 after buying an additional 5,967 shares during the last quarter. Cardinal Capital Management increased its position in C R Bard by 1.3% in the third quarter. Cardinal Capital Management now owns 23,280 shares of the medical instruments supplier’s stock valued at $5,221,000 after buying an additional 308 shares during the last quarter. Quantitative Investment Management LLC increased its position in C R Bard by 1,790.5% in the third quarter. Quantitative Investment Management LLC now owns 39,700 shares of the medical instruments supplier’s stock valued at $8,903,000 after buying an additional 37,600 shares during the last quarter. Glenview State Bank Trust DEPT. increased its position in C R Bard by 6.0% in the third quarter. Glenview State Bank Trust DEPT. now owns 7,645 shares of the medical instruments supplier’s stock valued at $1,715,000 after buying an additional 431 shares during the last quarter. Finally, Valley National Advisers Inc. increased its position in C R Bard by 17.2% in the third quarter. Valley National Advisers Inc. now owns 19,553 shares of the medical instruments supplier’s stock valued at $4,385,000 after buying an additional 2,866 shares during the last quarter. 86.89% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “C R Bard Inc (BCR) Short Interest Update” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/05/16/c-r-bard-inc-bcr-short-interest-update.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

5 Day Chart for NYSE:BCR

Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with MarketBeat.com's FREE daily email newsletter.